secwatch.observer — SEC 8-K summary
======================================

Issuer:     Annovis Bio, Inc. (ANVS)
CIK:        0001477845
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0001104659-24-116086
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Annovis Bio Q3 net loss $0.97/share; FDA clears Phase 3 studies for buntanetap in early AD
--------------------------------------------------------------------------------

- FDA granted clearance for pivotal Phase 3 studies: a 6-month symptomatic and an 18-month disease-modifying trial in early Alzheimer's disease.
- Cash and cash equivalents of $13.6M as of Nov 8, 2024; management says runway extends into Q1 2025 Phase 3 start.
- Q3 total operating expenses were $4.4M, down sharply from $14.9M a year ago; R&D was $2.7M vs $13.9M.
- Net loss per share (basic/diluted) was $0.97, compared to $1.63 in Q3 2023.
- Filed three new combination-therapy patents for buntanetap with dulaglutide, sildenafil, or both.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1477845/000110465924116086/0001104659-24-116086-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1477845/000110465924116086/tm2427939d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-116086

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer